{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:26:01Z","timestamp":1787199961467,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Objective<\/jats:title>\n To evaluate the real-world efficacy and safety of the bispecific antibody faricimab in Chinese patients with neocascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema secondary to retinal vascular occlusion (RVO-ME).<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This retrospective, single-center study included 63 patients (74 eyes: 47 nAMD, 19 DME, 8 RVO-ME); no subjects dropped out. Of the 74 eyes, 37.8% were treatment-na\u00efve and 62.2% were treatment-experienced. All eyes received intravitreal faricimab 6 mg in a three-dose loading regimen followed by pro re nata (PRN) retreatment. Best-corrected visual acuity (BCVA, ETDRS letters) and central macular thickness (CMT) were assessed at baseline, 1 month, 3 months, and final follow-up (mean follow-up, 23.9 \u00b1 12.3 weeks). Subgroup analyses by prior treatment status were performed.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Faricimab was associated with anatomical and functional improvements. In nAMD, treatment-na\u00efve patients (\n n<\/jats:italic>\n = 17) showed significant BCVA improvement (62.52 \u00b1 5.80 to 71.05 \u00b1 15.68 letters,\n P<\/jats:italic>\n = 0.037) and CMT reduction (477.86 \u00b1 189.45 to 324.19 \u00b1 137.62 \u03bcm,\n P<\/jats:italic>\n = 0.001) at final follow-up. Previously-treated nAMD patients (\n n<\/jats:italic>\n = 30) showed only a transient CMT reduction at 3 months (\n P<\/jats:italic>\n = 0.022) without sustained visual improvement. After the first injection, intraretinal fluid resolved in 90% of nAMD eyes that had IRF at baseline. After three loading doses, complete resolution of subretinal fluid and pigment epithelial detachment (PED) occurred in 66.7% and 31.3% of eyes, respectively. In DME, treatment-na\u00efve patients (\n n<\/jats:italic>\n = 9) achieved early BCVA improvement at 1 month (\n P<\/jats:italic>\n = 0.0273) and sustained benefit at final follow-up (\n P<\/jats:italic>\n = 0.0180), whereas previously-treated patients (\n n<\/jats:italic>\n = 10) showed delayed improvement at 3 months in both BCVA and CMT (\n P<\/jats:italic>\n = 0.0117 and 0.0195). In RVO-ME, BCVA improved significantly at 3 months and final follow-up (\n P<\/jats:italic>\n = 0.018 and 0.028), whereas CMT showed a nonsignificant decrease. No significant ocular or systemic adverse events were observed.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n In this short-term real-world study comprising three exploratory disease-specific cohorts of Chinese patients, faricimab was associated with favorable anatomical and functional outcomes and was well tolerated, with the most pronounced benefit in treatment-na\u00efve nAMD eyes. Responses in DME and RVO-ME were more variable and appeared to be influenced by prior treatment history; these subgroup analyses were exploratory, and larger prospective studies are warranted.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1909782","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:35Z","timestamp":1787199335000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Short-term morphological and functional outcomes of intravitreal faricimab for chorioretinal disorders: a real-world study in a Chinese population"],"prefix":"10.3389","volume":"13","author":[{"given":"Enzhong","family":"Jin","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Peking University People's Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Ocular Disease and Optometry Science, Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People's Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Ocular Disease and Optometry Science, Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijie","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Beijing Yanhua Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People's Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Ocular Disease and Optometry Science, Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People's Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Ocular Disease and Optometry Science, Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Qian","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Peking University People's Hospital","place":["Beijing, China"]},{"name":"Beijing Key Laboratory of Ocular Disease and Optometry Science, Peking University People's Hospital","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100954","DOI":"10.1016\/j.preteyeres.2021.100954","article-title":"VEGFR1 signaling in retinal angiogenesis and microinflammation","volume":"84","author":"Uemura","year":"2021","journal-title":"Prog Retin Eye Res."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e001516","DOI":"10.1136\/bmjophth-2023-001516","article-title":"Neovascular age-related macular degeneration: disease pathogenesis and current state of molecular biomarkers predicting treatment response-a scoping review","volume":"9","author":"Dervenis","year":"2024","journal-title":"BMJ Open Ophthalmol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"Wong","year":"2016","journal-title":"Nat Rev Dis Primers."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1038\/s41433-021-01620-z","article-title":"Long-term outcomes of anti-VEGF treatment of retinal vein occlusion","volume":"36","author":"Spooner","year":"2022","journal-title":"Eye."},{"key":"B5","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1167\/iovs.66.1.47","article-title":"The landscape of vascular endothelial growth factor inhibition in retinal diseases","volume":"66","author":"Lin","year":"2025","journal-title":"Invest Ophthalmol Vis Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"CD007419","DOI":"10.1002\/14651858.CD007419.pub7","article-title":"Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis","volume":"2023","author":"Virgili","year":"2023","journal-title":"Cochrane Database Syst Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"CD012208","DOI":"10.1002\/14651858.CD012208.pub2","article-title":"Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration","volume":"5","author":"Li","year":"2020","journal-title":"Cochrane Database Syst Rev."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1038\/s41433-020-0861-9","article-title":"A systematic review of real-world evidence of the management of macular oedema secondary to branch retinal vein occlusion","volume":"34","author":"Ang","year":"2020","journal-title":"Eye."},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/IAE.0000000000003628","article-title":"Characteristics of age-related macular degeneration showing a poor response to three loading doses of anti\u2013vascular endothelial growth factor","volume":"43","author":"Song","year":"2023","journal-title":"Retina."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.survophthal.2022.04.001","article-title":"Switching between anti-VEGF agents in the management of refractory diabetic macular edema: a systematic review","volume":"67","author":"Madjedi","year":"2022","journal-title":"Surv Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"943915","DOI":"10.3389\/fbioe.2022.943915","article-title":"Application and mechanism of anti-VEGF drugs in age-related macular degeneration","volume":"10","author":"Song","year":"2022","journal-title":"Front Bioeng Biotechnol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 signalling and its role in retinal and choroidal vascular diseases: a review of preclinical data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye."},{"key":"B13","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40265-022-01713-3","article-title":"Faricimab: first approval","volume":"82","author":"Shirley","year":"2022","journal-title":"Drugs."},{"key":"B14","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/13543784.2021.1879791","article-title":"Faricimab: an investigational agent targeting the Tie-2\/angiopoietin pathway and VEGF-A for the treatment of retinal diseases","volume":"30","author":"Nicol\u00f2","year":"2021","journal-title":"Expert Opin Investig Drugs."},{"key":"B15","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","article-title":"Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials","volume":"399","author":"Heier","year":"2022","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(22)00018-6","article-title":"Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials","volume":"399","author":"Wykoff","year":"2022","journal-title":"Lancet."},{"key":"B17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study - 6 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3282","DOI":"10.1038\/s41433-023-02505-z","article-title":"Faricimab in neovascular AMD: first report of real-world outcomes in an independent retina clinic","volume":"37","author":"Stanga","year":"2023","journal-title":"Eye."},{"key":"B20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12886-025-04212-7","article-title":"Real-world outcomes of a loading phase with intravitreal faricimab in refractory neovascular age-related macular degeneration (nAMD) patients","volume":"25","author":"Yufeng","year":"2025","journal-title":"BMC Ophthalmol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1186\/s12886-020-01510-0","article-title":"Anatomical and functional responses in eyes with diabetic macular edema treated with \u201c1 + PRN\u201d ranibizumab: one-year outcomes in population of mainland China","volume":"20","author":"Lai","year":"2020","journal-title":"BMC Ophthalmol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.2147\/OPTH.S521384","article-title":"Faricimab outcomes in chorioretinal disorders: indian real-world analysis (FOCUS Study)","volume":"19","author":"Agrawal","year":"2025","journal-title":"Clin Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"8984313","DOI":"10.1155\/2017\/8984313","article-title":"Two-year outcome of aflibercept in patients with pigment epithelial detachment due to neovascular age-related macular degeneration (nAMD) refractory to ranibizumab","volume":"2017","author":"Tran","year":"2017","journal-title":"J Ophthalmol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","article-title":"One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration","volume":"13","author":"Cancian","year":"2024","journal-title":"Ophthalmol Ther."},{"key":"B25","doi-asserted-by":"publisher","first-page":"913","DOI":"10.3390\/jpm14090913","article-title":"Real-world efficacy of intravitreal faricimab for diabetic macular edema: a systematic review","volume":"14","author":"Nasimi","year":"2024","journal-title":"J Pers Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1001\/jamaophthalmol.2014.2350","article-title":"Disorganization of the retinal inner layers as a predictor of visual acuity in diabetic macular edema","volume":"132","author":"Sun","year":"2014","journal-title":"JAMA Ophthalmol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Wells","year":"2015","journal-title":"N Engl J Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month results of the BRAVO study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/j.ophtha.2010.02.022","article-title":"Ranibizumab for macular edema following central retinal vein occlusion: six-month results of the CRUISE study","volume":"117","author":"Brown","year":"2010","journal-title":"Ophthalmology."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1909782\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:15:36Z","timestamp":1787199336000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1909782\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":29,"alternative-id":["10.3389\/fmed.2026.1909782"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1909782","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1909782"}}